Subjects’ baseline characteristics
| Characteristic* . | LD cohort (n = 17) . | HD cohort (n = 17) . |
|---|---|---|
| Age at enrollment, median (range), y | 47.2 (20.5-72.9) | 52.5 (21.0-68.2) |
| Male/female | 12/5 | 10/7 |
| Years from transplant to consent, median (range) | 4.8 (1.6-9.7) | 3.4 (1.5-8.3) |
| Indication for HCT | ||
| Myeloid malignancy | 8 | 10 |
| Lymphoid malignancy | 7 | 7 |
| Mixed lineage hematologic malignancy | 2 | 0 |
| Intensity of HCT conditioning | ||
| Myeloablative | 11 | 12 |
| Nonmyeloablative | 6 | 5 |
| Hematopoietic cell source | ||
| Bone marrow | 1 | 3 |
| Peripheral blood | 15 | 13 |
| Umbilical cord | 0 | 1 |
| Unknown | 1 | 0 |
| Donor relationship | ||
| Related donor | 9 | 7 |
| Unrelated donor | 8 | 10 |
| Degree of HLA match | ||
| 6/6 | 3 | 0 |
| 8/8 | 1 | 2 |
| 10/10 | 12 | 13 |
| Mismatched | 1 | 2 |
| Years from HCT to cGVHD diagnosis, median (range) | 0.8 (0.2-2.5) | 0.9 (0.2-2.1) |
| Years from cGVHD diagnosis to consent, median (range) | 3.5 (0.6-8.5) | 2.4 (0.7-7.5) |
| Type of cGVHD onset relative to acute GVHD | ||
| Progressive | 3 | 2 |
| Quiescent | 6 | 9 |
| De novo | 8 | 6 |
| Type of cGVHD | ||
| Classic | 16 | 17 |
| Overlap | 1 | 0 |
| Global NIH score at baseline | ||
| Moderate | 1 | 1 |
| Severe | 16 | 16 |
| Median no. of involved organs (range) | 5 (2-8) | 5 (3-7) |
| No. of prior systemic treatments (median, range) | 5 (2-10) | 5 (3-10) |
| No. of concurrent systemic treatments, median (range) | 2 (1-4) | 2 (1-4) |
| Karnofsky performance status (median, range) | 80 (70-90) | 80 (60-90) |
| Characteristic* . | LD cohort (n = 17) . | HD cohort (n = 17) . |
|---|---|---|
| Age at enrollment, median (range), y | 47.2 (20.5-72.9) | 52.5 (21.0-68.2) |
| Male/female | 12/5 | 10/7 |
| Years from transplant to consent, median (range) | 4.8 (1.6-9.7) | 3.4 (1.5-8.3) |
| Indication for HCT | ||
| Myeloid malignancy | 8 | 10 |
| Lymphoid malignancy | 7 | 7 |
| Mixed lineage hematologic malignancy | 2 | 0 |
| Intensity of HCT conditioning | ||
| Myeloablative | 11 | 12 |
| Nonmyeloablative | 6 | 5 |
| Hematopoietic cell source | ||
| Bone marrow | 1 | 3 |
| Peripheral blood | 15 | 13 |
| Umbilical cord | 0 | 1 |
| Unknown | 1 | 0 |
| Donor relationship | ||
| Related donor | 9 | 7 |
| Unrelated donor | 8 | 10 |
| Degree of HLA match | ||
| 6/6 | 3 | 0 |
| 8/8 | 1 | 2 |
| 10/10 | 12 | 13 |
| Mismatched | 1 | 2 |
| Years from HCT to cGVHD diagnosis, median (range) | 0.8 (0.2-2.5) | 0.9 (0.2-2.1) |
| Years from cGVHD diagnosis to consent, median (range) | 3.5 (0.6-8.5) | 2.4 (0.7-7.5) |
| Type of cGVHD onset relative to acute GVHD | ||
| Progressive | 3 | 2 |
| Quiescent | 6 | 9 |
| De novo | 8 | 6 |
| Type of cGVHD | ||
| Classic | 16 | 17 |
| Overlap | 1 | 0 |
| Global NIH score at baseline | ||
| Moderate | 1 | 1 |
| Severe | 16 | 16 |
| Median no. of involved organs (range) | 5 (2-8) | 5 (3-7) |
| No. of prior systemic treatments (median, range) | 5 (2-10) | 5 (3-10) |
| No. of concurrent systemic treatments, median (range) | 2 (1-4) | 2 (1-4) |
| Karnofsky performance status (median, range) | 80 (70-90) | 80 (60-90) |
HCT, hematopoietic cell transplantation.
Tests of differences between 2 cohorts return P > .05 for all listed characteristics.